4.6 Review

Lactoferrin as a Component of Pharmaceutical Preparations: An Experimental Focus

Journal

PHARMACEUTICALS
Volume 16, Issue 2, Pages -

Publisher

MDPI
DOI: 10.3390/ph16020214

Keywords

lactoferrin; neurodegenerative diseases; intestinal bowel diseases; nanoparticles

Ask authors/readers for more resources

Lactoferrin is a versatile glycoprotein with potential therapeutic applications in the pharmaceutical field. It can be used as a bioactive component or carrier in various formulations such as nanoparticles and liposomes. Lactoferrin has shown promise in enhancing the activity of antibiotics and protecting drugs from degradation in the intestine. It can also be used as a delivery system for drugs that cannot cross the blood-brain barrier. This manuscript focuses on the therapeutic possibilities of lactoferrin-containing pharmaceutical preparations and its interactions with tissue receptors, with the aim of improving drug bioavailability and reducing antimicrobial resistance.
Lactoferrin is an 80 kDa monomeric glycoprotein that exhibits multitask activities. Lactoferrin properties are of interest in the pharmaceutical field for the design of products with therapeutic potential, including nanoparticles and liposomes, among many others. In antimicrobial preparations, lactoferrin has been included either as a main bioactive component or as an enhancer of the activity and potency of first-line antibiotics. In some proposals based on nanoparticles, lactoferrin has been included in delivery systems to transport and protect drugs from enzymatic degradation in the intestine, favoring the bioavailability for the treatment of inflammatory bowel disease and colon cancer. Moreover, nanoparticles loaded with lactoferrin have been formulated as delivery systems to transport drugs for neurodegenerative diseases, which cannot cross the blood-brain barrier to enter the central nervous system. This manuscript is focused on pharmaceutical products either containing lactoferrin as the bioactive component or formulated with lactoferrin as the carrier considering its interaction with receptors expressed in tissues as targets of drugs delivered via parenteral or mucosal administration. We hope that this manuscript provides insights about the therapeutic possibilities of pharmaceutical Lf preparations with a sustainable approach that contributes to decreasing the resistance of antimicrobials and enhancing the bioavailability of first-line drugs for intestinal chronic inflammation and neurodegenerative diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available